Compare PepsiCo, Inc. (PEP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Summit Therapeutics Inc — how do they compare? PepsiCo, Inc. trades at $125.97 (market cap $174.89B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: PepsiCo, Inc. is far larger — about 12.8× Summit Therapeutics Inc's market cap, and PepsiCo, Inc. pays a 4.61% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and Summit Therapeutics Inc for 16 Days on average.
| PEP | SMMT | |
|---|---|---|
Market Cap | $174.89B | $13.71B |
Volume | 23,968,864 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $26.38 |
52-Week Low | $123.64 | $12.43 |
Typical Hold Time | 107 Days | 16 Days |
Enterprise Value | $215.61B | $13.04B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $128.88, up 4.24% with strong earnings momentum as the company has beaten EPS estimates for four consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 10.78% net income margin and 51.59% ROE. Recent news highlights price adjustments for snack products and sponsorship changes, while analysts maintain a consensus price target of $146.77 representing 13.9% upside potential from current levels.
PepsiCo presents a mixed investment case with strong profitability metrics and consistent earnings beats offset by bearish technical indicators and margin pressure from recent price cuts. The company's stable cash flow generation and dividend payments provide downside protection, though competitive pressures and consumer resistance to higher prices remain key risks. Wall Street sentiment leans cautious with 67.4% hold ratings.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
